Drug Trial Radar · NCT05443126
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
265
Planned (sponsor's estimate)
Start
Sep 30, 2022
Primary completion
Mar 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Ellipses PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.
Conditions
- NSCLC
Interventions
EP0031Drug
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
Platinum chemotherapyDrug
One of either Cisplatin or Carboplatin. Both agents are potent platinum-based antineoplastic/alkylating agents administered as an IV infusion according to local practice and labels.
PemetrexedDrug
Pemetrexed is a chemotherapy medication and antifolate metabolic inhibitor administered as an IV infusion according to local practice and labels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Module B: Incidence of Dose-limiting Toxicity (DLTs ) during the first 21 days of EP0031 given in combination with SOC chemotherapy treatmentTime frame: First 21 days of treatment
Locations
52 sites in 8 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
Stanford University
Stanford, California · Recruiting
Georgetown University
Washington D.C., District of Columbia · Recruiting
Florida Cancer Specialist
Fort Myers, Florida · Terminated
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Florida Cancer Specialists & Research Institute
West Palm Beach, Florida · Recruiting
RUSH University Medical Center
Chicago, Illinois · Terminated
Northwestern University
Evanston, Illinois · Recruiting
University of Kentucky
Lexington, Kentucky · Terminated
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Karmanos
Detroit, Michigan · Terminated
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
The Ohio State University - Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Providence Portland Medical Centre
Portland, Oregon · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Withdrawn
Sarah Cannon Research Institute
Nashville, Tennessee · Terminated
MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Washington University - School of Medicine
Seattle, Washington · Recruiting
University of Washington - Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Centre François Baclesse
Caen, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Assistance Publique - Hôpitaux de Marseille
Marseille, France · Recruiting
Institut Gustave Roussy
Paris, France · Recruiting
Charité Comprehensive Cancer Center
Berlin, Germany · Recruiting
Universitätsklinikum Köln
Cologne, Germany · Recruiting
Ludwig-Maximilians-Universität München (LMU)
München, Germany · Not yet recruiting
Centro di Riferimento Oncologico IRCCS
Aviano, Italy · Recruiting
IRCCSS AOU Bologna
Bologna, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Not yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Istituto Nazionale Tumori Regina Elena
Roma, Italy · Recruiting
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Torino, Italy · Recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie
Warsaw, Poland · Not yet recruiting
Hospital Universitario de A Coruña
A Coruña, Spain · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.